Oyster Point Pharma, Inc. Common Stock
OYST
OYST was delisted on the 30th of December, 2022.
43 hedge funds and large institutions have $464M invested in Oyster Point Pharma, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 7 closing their positions.
40% more capital invested
Capital invested by funds: $331M → $464M (+$134M)
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
5% more funds holding
Funds holding: 41 → 43 (+2)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1.26% less ownership
Funds ownership: 63.52% → 62.26% (-1.3%)
15% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$31.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.29M |
| 3 |
First Manhattan
New York
|
+$3.07M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.68M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$681K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VM
VV Manager
Boston,
Massachusetts
|
-$23.5M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$5.64M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$5.5M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$4.76M |
| 5 |
BlackRock
New York
|
-$1.36M |
OYST Hedge Fund Activity: Q1 2020 in Review
43 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in Oyster Point Pharma, Inc. Common Stock (OYST) for Q1 2020, worth a combined $464M — up 40% from $331M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new OYST positions and 7 closed out — a net gain of 2 holders — while 11 added to existing stakes and 13 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $31.4M. The largest seller was VV Manager, exiting entirely with an estimated $23.5M sold.
- 43 institutional investors held Oyster Point Pharma, Inc. Common Stock (OYST) as of Q1 2020, up from 41 in Q4 2019.
- Funds reported $464M of Oyster Point Pharma, Inc. Common Stock stock for Q1 2020, up 40% quarter-over-quarter.
- 9 funds opened new Oyster Point Pharma, Inc. Common Stock positions in Q1 2020 and 7 closed out, a net change of +2 holders.
- The largest Oyster Point Pharma, Inc. Common Stock buyer in Q1 2020 was RTW Investments, an estimated $31.4M added.
- The largest Oyster Point Pharma, Inc. Common Stock seller in Q1 2020 was VV Manager, an estimated $23.5M sold.
Based on aggregated 13F filings for Q1 2020.